Absci Corporation (ABSI) Draws Full Buy Consensus With 150% Upside Potential

Core Viewpoint - Absci Corporation (NASDAQ:ABSI) is identified as a promising investment opportunity with a consensus buy rating among analysts, indicating significant upside potential based on recent developments in its drug programs [1]. Group 1: Analyst Ratings and Price Targets - As of December 24, Absci Corporation has a consensus buy rating from nine analysts, with a median price target of $9, suggesting an upside potential of 150.70% [1]. - H.C. Wainwright reaffirmed a 'Buy' rating on December 17, raising the price target from $7 to $8, reflecting an upside potential of 125% due to the incorporation of ABS-201 into the company's financial model [2]. Group 2: Product Development and Clinical Evidence - The ABS-201 program is designed to enhance hair follicle growth phases, potentially reducing hair shedding, supported by strong preclinical evidence [3]. - New preclinical data presented on December 11 indicates that ABS-201 may effectively stimulate hair growth in human scalp tissue by targeting the prolactin receptor (PRLR), which aids in stem cell preservation and prolongs the active growth phase of hair follicles [4]. Group 3: Company Overview - Absci Corporation is a Washington-based generative AI drug-creation company founded in 2011, integrating AI with scalable wet lab technologies to develop unique antibody therapeutics [5].